Free Trial
→ Read this or regret it forever (From Porter & Company) (Ad)tc pixel
NASDAQ:HSDT

Solana Q3 2024 Earnings Report

Solana logo
$2.22 +0.07 (+3.26%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$2.22 +0.00 (+0.23%)
As of 05/8/2026 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Solana EPS Results

Actual EPS
-$742.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Solana Revenue Results

Actual Revenue
$0.05 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Solana Announcement Details

Quarter
Q3 2024
Date
11/12/2024
Time
After Market Closes
Conference Call Date
Tuesday, November 12, 2024
Conference Call Time
4:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Solana's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Solana Earnings Headlines

Head to Head Comparison: Solana (NASDAQ:HSDT) & NeuroPace (NASDAQ:NPCE)
May 8 at 3:57 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30764872
Jito Foundation and Solana Company Announce Strategic Partnership to Enhance Institutional Adoption of Solana in APAC Region
May 6, 2026  |  quiverquant.comQ
Move your Money Now: This has only happened 4 times in 50 years
47-year Wall Street veteran Louis Navellier says a rare market pattern is forming for only the fifth time in his career - each previous instance was triggered by a Federal Reserve shift and preceded gains of 1,100% to 2,900% in select small-cap stocks. On May 13 at 1 p.m. ET, Navellier is hosting the 10X Fed Shock Summit to walk through what he sees unfolding before the new Fed Chair takes over on May 15. Sign up and receive his 53-stock 'Exclusion List' free, plus his single highest-conviction pick named live.tc pixel
May 10 at 1:00 AM  |  Stansberry Research (Ad)
Jito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific Region
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288875/0/en/jito-foundation-and-solana-company-nasdaq-hsdt-announce-strategic-partnership-to-expand-institutional-solana-infrastructure-across-asia-pacific-region.html
Solana (HSDT) price target decreased by 12.50% to 3.57
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/solana-hsdt-price-target-decreased-by-12-50-to-3-57/ar-AA21Wxcf
Solana Company Strengthens Board with Crypto Finance Experts
April 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/HSDT/pressreleases/1520499/solana-company-strengthens-board-with-crypto-finance-experts/
See More Solana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Solana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solana and other key companies, straight to your email.

About Solana

Helius Medical Technologies, Inc. (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics. Frameworks of care vary by region but typically involve coordinated therapy protocols that combine the wearable stimulator, physical exercises and clinician-led monitoring. Helius supports its clinical users with training, device management and remote patient engagement tools to optimize rehabilitation outcomes.

Beyond its core PoNS offering, Helius is advancing an at-home digital therapy program that integrates software-guided exercises and telehealth support. The company collaborates with research institutions and rehabilitation centers to broaden the evidence base for its technology and explore applications in conditions such as mild traumatic brain injury, multiple sclerosis and stroke recovery. Ongoing clinical studies aim to expand indications and refine therapy protocols.

Founded in 2015 and headquartered in Toronto, Ontario, Helius Medical Technologies is led by President and Chief Executive Officer Dan M. Toutant. Since its inception, the company has pursued regulatory clearances across key markets and built partnerships with rehabilitation specialists to bring neuromodulation therapies to patients worldwide.

View Solana Profile
Earnings Tools